Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21641661 | 0.97 | MEN1 (0.46) | MEN1KMT2AEPHX1NOS1 | |
| SCHEMBL27562845 | 0.97 | MEN1 (0.46) | MEN1KMT2AEPHX1NOS1 | |
| SCHEMBL19485090 | 0.74 | — | — | |
| SCHEMBL8320893 | 0.74 | — | — | |
| SCHEMBL8320888 | 0.72 | — | — | |
| SCHEMBL19484938 | 0.69 | MEN1 (0.43) | MEN1KMT2AEPHX1 | |
| SCHEMBL11571739 | 0.67 | — | — | |
| SCHEMBL9910982 | 0.67 | EPHX1 (0.36) | MEN1KMT2AEPHX1NOS1 | |
| SCHEMBL1276388 | 0.65 | MEN1 (1.00) | MEN1KMT2AEPHX1 | |
| SCHEMBL10668659 | 0.65 | NOS1 (0.40) | MEN1KMT2ANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10653795-B2 | — | PTMS, MSN, CD44 | MEN1 3272/4885KMT2A 3217/4885EPHX1 126/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | MEN1 3497/4885KMT2A 2556/4885EPHX1 164/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | MEN1 3497/4885KMT2A 2556/4885EPHX1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.